Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma

16 Feb 2015

Abstract excerpt

Although serum beta-2 microglobulin (B2M) has been suggested as a prognostic factor for mantle cell lymphoma (MCL), additional data are necessary to confirm its role. Between November 2005 and July 2014, a total of 52 patients with MCL were identified from the database of Asan Medical Center, Seoul, Korea. Pretreatment serum B2M information was available in 50 patients (96%). Overall survival (OS) was compared...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to HER2/EGFR in Cancer Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25689467
DOI: 10.1002/hon.2188

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 11 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphomaPMID 25689467Read ↗

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsSemantic proximity Read ↗

Mantle cell lymphoma: evolving management strategies.Semantic proximity Read ↗

Risk factors for etiology and prognosis of mantle cell lymphoma.Semantic proximity Read ↗

Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma.Semantic proximity Read ↗

[Mantle cell lymphoma: Towards a personalized therapeutic strategy?].Semantic proximity Read ↗

Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.Semantic proximity Read ↗

Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).Semantic proximity Read ↗

Prognostic Value and Computer Image Analysis of p53 in Mantle cell LymphomaSemantic proximity Read ↗

Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.Semantic proximity Read ↗

Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches.Semantic proximity Read ↗

p53 immunohistochemistry must be confirmed by TP53 next generation sequencing for accurate risk stratification of patients with mantle cell lymphoma.Semantic proximity Read ↗

Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.